NCT06988150

Small Intestinal Bacterial Overgrowth (SIBO) in Pancreatic Adenocarcinoma (PDAC)

RecruitingOBSERVATIONAL

Trial Details

Start: 2025-04-14Est. Completion: 2026-04-14

Enrollment target: 100 participants

Locations

Cedars-Sinai Medical Center, Los Angeles, California, United States

Contact

Abrahm Leviabrahm.levi@cshs.org 310-248-8084

Other microbiome trials you might be interested in

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerPhase 1Recruiting

Metastatic Lung Small Cell CarcinomaMetastatic Malignant Solid NeoplasmMetastatic Neuroendocrine CarcinomaMetastatic Pancreatic AdenocarcinomaStage III Lung Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Lung Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8Unresectable Lung Small Cell CarcinomaUnresectable Malignant Solid NeoplasmUnresectable Neuroendocrine CarcinomaUnresectable Pancreatic Adenocarcinoma

This phase I trial tests the safety, side effects and best dose of BAY 1895344 when given together with usual chemothera…

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.